Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
iSpecimen Inc. (ISPC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
8-K
| Quarterly results |
| 06/01/2023 |
4
| Curley Tracy (CEO, CFO and Treasurer) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Bought 4,400 shares
@ $1.25, valued at
$5.5k
|
|
| 05/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/17/2023 |
4
| Basile Joseph J. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 63 shares
@ $0 |
|
| 05/17/2023 |
4
| Brooks John L. III (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 125 shares
@ $0 |
|
| 05/17/2023 |
4
| Mullan Jill (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 92 shares
@ $0 |
|
| 05/17/2023 |
4
| Ianelli Christopher (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 92 shares
@ $0 |
|
| 05/17/2023 |
4
| Ross Andrew L. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 125 shares
@ $0 |
|
| 05/17/2023 |
4
| Gullans Steven R. Ph.D. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 125 shares
@ $0 |
|
| 05/04/2023 |
8-K
| Quarterly results|
Docs:
|
"iSpecimen Inc. Condensed Balance Sheets March 31, 2023 December 31, 2022 ASSETS Current assets: Cash and cash equivalents $ 3,762,654 $ 15,308,710 Available-for-sale securities 7,259,482 — Accounts receivable – unbilled 1,584,440 2,327,789 Accounts receivable, net of allowance for doubtful accounts of $383,789 and $230,999 at March 31, 2023 and December 31, 2022, respectively 3,005,832 1,597,915 Prepaid expenses and other current assets 312,900 300,434 Tax credit receivable 34,669 140,873 Total current assets 15,959,977 19,675,721 Property and equipment, net 195,293 225,852 Internally developed software, net 5,610,007 4,503,787 Operating lease right-of-use asset 146,193 184,692 Security deposits 27,601 27,601 Total assets $ 21,939,071 $ 24,617,653 LIABILITIES AND STOCKHOLDERS’ EQUITY Curre...",
"This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results ma..." |
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/17/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/14/2023 |
8-K
| Quarterly results|
Docs:
|
"iSpecimen Inc. Condensed Balance Sheets December 31, December 31, 2022 2021 Unaudited ASSETS Current assets: Cash $ 15,308,710 $ 27,738,979 Accounts receivable - unbilled 2,327,789 1,739,020 Accounts receivable, net of allowance for doubtful accounts of $230,999 and $269,170 at December 31, 2022 and 2021, respectively 1,597,915 3,002,442 Prepaid expenses and other current assets 300,434 327,035 Tax credit receivable, current portion 140,873 140,873 Total current assets 19,675,721 32,948,349 Property and equipment, net 225,852 32,781 Internally developed software, net 4,503,787 2,710,867 Operating lease right-of-use asset 184,692 — Security deposits 27,601 27,601 Total assets $ 24,617,653 $ 35,719,598 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,459,063 $ 8...",
"SUPPLY HEALTHCARE PROVIDERS DEMAND LIFE SCIENCE RESEARCHERS" |
|
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 01/19/2023 |
4
| Ianelli Christopher (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
Exercised 845 options
@ $1, valued at
$845 |
|
| 01/19/2023 |
4
| Mullan Jill (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Exercised 66,637 options
@ $1, valued at
$66.6k
|
|
| 01/19/2023 |
4
| Mullan Jill (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
|
|
| 01/13/2023 |
4
| Gullans Steven R. Ph.D. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
|
|
| 01/13/2023 |
4
| Basile Joseph J. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
|
|
| 01/13/2023 |
4
| Brooks John L (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
|
|
| 01/13/2023 |
4
| Scholl George H. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
|
|
| 01/13/2023 |
4
| Ross Andrew L. (Director) has filed a Form 4 on iSpecimen Inc.|
Txns:
| Granted 10,000 options
@ $1.41, valued at
$14.1k
|
|
| 01/12/2023 |
SC 13G/A
| Empery Asset Management, LP reports a 4.7% stake in iSpecimen Inc. |
|
|
|